$LTRN — Schrödinger is showing why OMAI could be much more valuable than the Market thinks

{"summary": "Author argues Schrödinger's AI deals validate Lantern's OMAI/ZetaOmics scientific-AI model, making LTRN undervalued relative to that opportunity.", "reason": "The author provides a fundamental thesis linking industry-wide validation of AI models to the specific valuation of LTRN, citing specific industry benchmarks as a catalyst for potential revaluation.", "ideas": [{"symbol": "LTRN", "direction": "long", "thesis": "The author contends that Bristol Myers Squibb deploying Schrödinger's AI co-scientist Bunsen and NEA/RA Capital's $55M investment into Tectora validate the scientific-AI model that Lantern is pursuing via OMAI/ZetaOmics. They argue Schrödinger is a blueprint for what OMAI could become, and given LTRN's tiny valuation, OMAI would not need to match Schrödinger for the impact to be substantial. The stated requirement is execution, with the risk that OMAI must prove pharma demand and raise external capital at a meaningful valuation.", "thesis_short": "Schrödinger AI validation makes LTRN's OMAI undervalued", "quote": "If OMAI can prove that pharma companies want its scientific infrastructure, and raise external capital at a meaningful valuation, Schrödinger provides a very interesting blueprint for what could happen.", "confidence": 0.7, "sentiment": 0.7, "timeframe": "unspecified"}], "model": "gemini-3.1-flash-lite", "failure_count": 0, "verified": true, "extraction_model": "deepseek-flash"}